Company

Aligos Therapeutics, Inc.

Headquarters: South San Francisco, CA, United States

Employees: 93

CEO: Dr. Lawrence M. Blatt MBA, Ph.D.

NASDAQ: ALGS +8.74%

Market Cap

$37.0 Million

USD as of July 1, 2024

Market Cap History

Aligos Therapeutics, Inc. market capitalization over time

Evolution of Aligos Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Aligos Therapeutics, Inc.

Detailed Description

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-àŸ agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Aligos Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: ALGS wb_incandescent

Stock: FSX: 5WK wb_incandescent

Details

Headquarters:

One Corporate Drive

2nd Floor

South San Francisco, CA 94080

United States

Phone: 800-466-6059